Publikation
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Wissenschaftlicher Artikel/Review - 18.02.2011
Viale G, Thürlimann Beat, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, Láng I, Colleoni M, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups
Viale, G
12
0
Regan, M M
13
0
Dell'orto, P
3
0
Mastropasqua, M G
2
0
Maiorano, E
2
0
Rasmussen, B B
1
0
Macgrogan, G
4
0
Forbes, J F
10
0
Paridaens, R J
2
0
Colleoni, M
25
0
Láng, I
5
0
Thürlimann, Beat
259
14
Mouridsen, H
3
0
Mauriac, L
4
0
Gelber, R D
40
0
Price, K N
20
0
Goldhirsch, A
54
0
Gusterson, B A
4
0
Coates, A S
35
0
for the BIG 1-98 Collaborative and International Breast Cancer Study Groups,
1
0